Literature DB >> 2303716

Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes.

R J Barth1, S N Bock, J J Mulé, S A Rosenberg.   

Abstract

Tumor infiltrating lymphocytes (TIL) were cultured from multiple methylcholanthrene-induced sarcomas under four different conditions: either low-dose (10 U/ml) or high-dose (1000 U/ml) rIL-2 was used with Ag stimulation by irradiated autologous tumor and splenocytes starting either at day 1 or day 10 of culture. TIL grown from four antigenically distinct sarcomas in low-dose rIL-2 were specifically lytic in vitro to their tumor of origin in 13 of 15 (87%) lytic cultures whereas only 8 of 28 (29%) lytic TIL cultures grown in high-dose rIL-2 showed specificity. TIL cultured in low-dose rIL-2 with Ag stimulation on day 1 of culture proliferated at a rate equal to TIL grown in high-dose rIL-2 and maintained their specificity for over 3 mo in culture. Cytolysis by specific TIL was MHC-restricted. TIL with in vitro specificity were therapeutically effective in eliminating established micrometastases in murine models. These investigations demonstrate that CTL derived from tumor-bearing mice can be used to define unique tumor-associated Ag on at least four different sarcomas and may be valuable in studies of the biologic nature of these Ag and in the adoptive immunotherapy of tumors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2303716

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

Review 2.  Progress in the development of immunotherapy for the treatment of patients with cancer.

Authors:  S A Rosenberg
Journal:  J Intern Med       Date:  2001-12       Impact factor: 8.989

3.  Tumor-primed, in vitro-activated CD4+ effector T cells establish long-term memory without exogenous cytokine support or ongoing antigen exposure.

Authors:  Li-Xin Wang; Gregory E Plautz
Journal:  J Immunol       Date:  2010-04-09       Impact factor: 5.422

Review 4.  The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.

Authors:  I M Svane; M Boesen; A M Engel
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

5.  Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.

Authors:  A D Roth; S Dupuis; P Alberto
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

6.  Use of recombinant interleukin-2 to enhance adoptive transfer of resistance to Listeria monocytogenes infection.

Authors:  M Haak-Frendscho; C J Czuprynski
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

7.  The development of gene therapy for the treatment of cancer.

Authors:  S A Rosenberg; W F Anderson; M Blaese; P Hwu; J R Yannelli; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; S E Ettinghausen
Journal:  Ann Surg       Date:  1993-10       Impact factor: 12.969

8.  Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA.

Authors:  B H O'Neil; Y Kawakami; N P Restifo; J R Bennink; J W Yewdell; S A Rosenberg
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

9.  Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.

Authors:  N P Restifo; F Esquivel; A L Asher; H Stötter; R J Barth; J R Bennink; J J Mulé; J W Yewdell; S A Rosenberg
Journal:  J Immunol       Date:  1991-08-15       Impact factor: 5.422

10.  Induction of interleukin-2 receptor by tumor necrosis factor alpha on cultured ovarian tumor-associated lymphocytes.

Authors:  C G Ioannides; B Fisk; B Tomasovic; R Pandita; B B Aggarwal; R S Freedman
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.